Speakers
--------
N/A
Peptide therapeutics has once again become the focus of innovative
drug development. As potential therapeutics, peptides offer several
advantages over small molecules (increased specificity) and antibodies
(small size). However, delivery and sensitivity to serum and tissue
proteases coupled with short serum half-life has remained a major
therapeutic stumbling block. Cambridge Healthtech Instituteâ€™s
Inaugural Peptide Therapeutics addresses recently developed
technologies to overcome these issues thus allowing therapeutic
peptides to fulfill their promise as a widely accepted drug class.